ObjectiveTo determine the efficiency and safety of combined treatment of Zhenyuan capsule with lorazepam for anxiety symptoms in the elderly patients with chronic heart failure (CHF).Methods Hamilton Anxiety Scale (HAMA) was employed to assess 315 CHF patients (≥60 years old) admitted in our department from January 2013 to February 2015. Eighty-one of them with anxiety symptoms were screened out and then randomly divided into 2 groups, lorazepam alone group (control group,n=40) and Zhenyuan capsule combined with lorazepam group (treatment group,n=41). Besides these, conventional drug treatment, psychological intervention and rehabilitation training were given to both groups. In 4 weeks later, they were compared by scores of heart functions, HAMA scores, Self-rating Anxiety Scale (SAS) score, left ventricular ejection fraction (LVEF), and serum level of N-terminal B-type natriuretic peptide (NT-proBNP). Results The treatment group had better heart function, HAMA score and SAS score than the control group (P<0.05). LVEF and NT-proBNP level were both improved in the 2 groups, with more obviously in treatment group, but there was no significant difference between the 2 groups (P>0.05).Conclusion Zhenyuan capsule combined with lorazepam improves the curative effect on anxiety symptoms in elderly CHF patients, and has less adverse reaction, good compliance and better efficiency than lorazepam alone.%目的：探讨振源胶囊联合劳拉西泮治疗老年慢性心力衰竭（CHF）伴发焦虑症状患者的有效性和安全性。方法选择2013年1月至2015年2月在北京老年医院门诊及住院收治的315例≥60岁的CHF患者，应用汉密尔顿焦虑量表（HAMA）评价，从中筛选出并发焦虑症状的患者81例，随机分成对照组40例和治疗组41例。两组均按心力衰竭指南给予正规药物治疗、心理干预、康复训练，对照组口服劳拉西泮抗焦虑治疗，治疗组口服劳拉西泮+振源胶囊，观察时间为4周。比较两组治疗前后的心功能分级、HAMA评分、焦虑自评量表（SAS）评分，左室射血分数（LVEF）、血浆氨基端B型利钠肽原（NT-proBNP）的变化。结果治疗组患者心功能分级、HAMA评分、SAS评分的改善均优于对照组，差异有统计学意义（P＜0.05）；两组患者LVEF、NT-proBNP均较治疗前好转，治疗组好转更明显，两组比较差异无统计学意义（P＞0.05）。结论振源胶囊联合劳拉西泮能显著提高CHF伴发焦虑症状患者的临床疗效，不良反应少，依从性好，优于单用劳拉西泮治疗。
展开▼
